<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01627665</url>
  </required_header>
  <id_info>
    <org_study_id>P081208</org_study_id>
    <nct_id>NCT01627665</nct_id>
  </id_info>
  <brief_title>Pharmacogenomic Study on PKD/PKC of Dabigatran Etexilate and Rivaroxaban</brief_title>
  <acronym>DRIVING</acronym>
  <official_title>New Oral Anticoagulant Drugs Dabigatran Etexilate and Rivaroxaban: Influence of Genetic Factors in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will address the impact of genetical variation of a protein involved in the
      intestinal absorption of two new anticoagulants : Dabigatran etexilate and Rivaroxaban.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will address the impact of genetical variation of a protein involved in the
      intestinal absorption of two new anticoagulants : Dabigatran etexilate and Rivaroxaban.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC of plasma concentrations of the drugs</measure>
    <time_frame>over 24h after single oral dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>PKD of the drugs</measure>
    <time_frame>over 24h after single oral dose</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>D-&gt;R-&gt;C+R</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>sequence of treatment: Dabigatran after rivaroxaban after chlarythromycin in association with rivaroxaban</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D-&gt;R-&gt;C+D</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>sequence of treatment: Dabigatran after rivaroxaban after chlarythromycin in association with Dabigatran</description>
  </arm_group>
  <arm_group>
    <arm_group_label>R-&gt;D-&gt;C+D</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>sequence of treatment: rivaroxaban after Dabigatran after chlarythromycin in association with Dabigatran</description>
  </arm_group>
  <arm_group>
    <arm_group_label>R-&gt;D-&gt;C+R</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>sequence of treatment: rivaroxaban after Dabigatran after chlarythromycin in association with rivaroxaban</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>D-&gt;R-&gt;C+R</intervention_name>
    <description>one oral dose DABIGATRAN 300 mg -&gt; RIVAROXABAN 40 mg -&gt; 1g/day CLARITHOMYCINE with RIVAROXABAN 40 mg</description>
    <arm_group_label>D-&gt;R-&gt;C+R</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>D-&gt;R-&gt;C+D</intervention_name>
    <description>one oral dose DABIGATRAN 300 mg -&gt; RIVAROXABAN 40 mg -&gt; 1g/day CLARITHOMYCINE with one oral dose DABIGATRAN 300 mg</description>
    <arm_group_label>D-&gt;R-&gt;C+D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>R-&gt;D-&gt;C+D</intervention_name>
    <description>RIVAROXABAN 40 mg -&gt; one oral dose DABIGATRAN 300 mg -&gt; 1g/day CLARITHOMYCINE with one oral dose DABIGATRAN 300 mg</description>
    <arm_group_label>R-&gt;D-&gt;C+D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>R-&gt;D-&gt;C+R</intervention_name>
    <description>RIVAROXABAN 40 mg -&gt; one oral dose DABIGATRAN 300 mg -&gt; 1g/day CLARITHOMYCINE with RIVAROXABAN 40 mg</description>
    <arm_group_label>R-&gt;D-&gt;C+R</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy participants

          -  Aged between 18-35 years inclusive

          -  Male

          -  Caucasian

          -  Body mass index (BMI) between 18 and 27 kg per m² inclusive.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anne Blanchard, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CIC HEGP</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CIC Hopital europeen george pompidou</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 27, 2012</study_first_submitted>
  <study_first_submitted_qc>June 21, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 26, 2012</study_first_posted>
  <last_update_submitted>October 8, 2014</last_update_submitted>
  <last_update_submitted_qc>October 8, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 9, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>dabigatran</keyword>
  <keyword>rivaroxaban</keyword>
  <keyword>PKC</keyword>
  <keyword>PKD</keyword>
  <keyword>p-glycoprotein</keyword>
  <keyword>polymorphism</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rivaroxaban</mesh_term>
    <mesh_term>Dabigatran</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

